Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of illness in North America and Europe (SABINE) study

M. Leahy, X. Garcia del muro, P. Reichardt, I. Judson, A. Staddon, J. Verweij, A. Baffoe-Bonnie, L. Jönsson, A. Musayev, N. Justo, T. Burke, J. Y. Blay, Annette Reichardt, Sebastian Bauer, Sahra Rauhut, Clemens Wendtner, Lars Pester, William Sebag, Francois Goldwasser, Wilana JepiralLoïc Chaigneau, Ludivine Roy, Binh Bui-Nguyen, Sabrina Albert, Umberto Basso, Anna Roma, Virgina Ferraresi, Maria Tedeschi, Emanuela Marchesi, Jaap Verweij, Marianne Mol, Kamphuis Juliëtte Kamphuis, Antonio Casado Herraéz, Hortensia Peleteiro, Jiménez Laura Jiménez, Gajete María Gajete, Antonio López Pousa, Rosa Sanchez, Hans Hagberg, Quincy Chu, Margo Miller, Sant P. Chawla, Victoria Chu, Arthur Staddon, Zackory Burns, Brian Samuels, Ryan Dobler, Robin Gustin, Sarah Welby, Ian Judson, Galina Petrikova, Larry Hayward, Paul Ramage

Research output: Contribution to journalArticlepeer-review

Abstract

Background: To describe chemotherapy treatment patterns and clinical outcomes in metastatic soft tissue sarcoma (mSTS) patients with favorable response to chemotherapy. Patients and methods: Multicenter (25) multi-country (9) retrospective chart review of mSTS patients with favorable response to chemotherapy, defined as stable disease or better following four cycles. Results: Two hundred and thirteen patients (58% female; mean age 54.7 years) received a mean of 2.7 lines of chemotherapy and 5.2 cycles per line. The most common first-line regimens were doxorubicin (34%) and anthracycline plus ifosfamide (30%). Favorable response was achieved by 83% to first-line and 42% and 38% in second-and third-line chemotherapy. The most common reason for chemotherapy discontinuation in lines with a favorable response was reaching a predefined number of cycles in first line (64% of 213) and disease progression in second or later lines (41% of 138). The mean time off chemotherapy was 38.0 weeks after first line, falling to 2.7-6.4 weeks in second or later lines. Median overall and progression-free survival were 23.5 (95% confidence interval 20.5-28.1) and 8.3 (7.4-9.9) months from first favorable response to chemotherapy. Conclusions: mSTS patients achieving favorable response to chemotherapy have poor outcomes. Additional treatment options are needed.

Original languageEnglish
Article numbermds070
Pages (from-to)2763-2770
Number of pages8
JournalAnnals of Oncology
Volume23
Issue number10
DOIs
Publication statusPublished - Oct 2012

Keywords

  • Chemotherapy
  • Palliative care
  • Retrospective studies
  • Sarcoma
  • Soft tissue neoplasms

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint

Dive into the research topics of 'Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of illness in North America and Europe (SABINE) study'. Together they form a unique fingerprint.

Cite this